NEW YORK, February 15, 2018 /PRNewswire/ --
There has been positive growth in the medical devices industry over the course of recent years, which is attributed to technological advancements made in development of devices for unmet medical needs. According to Transparency Market Research the global medical device technology market has showcased significant growth over the past few years and is anticipated is projected to grow at a robust CAGR of 4.6% over the forecast period of 2017 to 2025. At this growth rate the market is projected to reach a value of $563,886.5 million by 2025, from $377,562.4 million in 2016. The report points out important market related factors, such as increase in prevalence of cancer and rare diseases, as well as rise in demand for regenerative and cell-based therapies. ORHUB, Inc. (OTC: ORHB), Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC), Simulations Plus, Inc. (NASDAQ: SLP), Fluidigm Corporation (NASDAQ: FLDM), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX)
A pharmaceutical and medical devices industry analyst in Visiongain, Moses Akintomide-Akinwamide, explained: "We expect the increasing move towards personalised therapy to contribute to the expansion of the medical devices market, particularly between 2017 and 2023. Innovations in the field of diagnostics will propel the launch of devices which incorporate biomarkers; leading to swifter patient diagnosis and monitoring… Competition within some of the currently fast growing sectors, such as the cardiology and neurological sectors, will intensify due to the expected launch of innovative products by major companies in mature markets. Moreover, medical device manufacturers will be required to display a high level of cost-effectiveness for their products due to tighter regulatory and reimbursement policies, especially in the emerging economies."
ORHUB, Inc. (OTC: ORHB) on February 6th announced, "that $3.2 million dollars has been successfully raised to further the Company's reach into the marketplace with its revolutionary healthcare IT Vertical Specific Software, which is poised to transform the business of surgery by delivering real-time, casebased surgical data analytics.
This latest funding comes on the heels of the recent warrant program that, at the close of 2017, yielded the Company $3.8 million in working capital. More than $7.0 million raised in past 60 days to drive national sales and scale operations for revolutionary healthcare software.
Offering enhanced capabilities over traditional EHR solutions in the operating room, ORHub's software creates a value-based solution that streamlines surgical care delivery by tracking comprehensive data using proprietary technology. The Company's software has international applications and is particularly ripe for deployment in the United Kingdom, where such solutions are being urgently sought.
ORHub has already secured commitments from three additional major hospitals and has generated interest from countless others. This timely funding will enable the Company's management to meet this demand. ORHub recently announced gross proceeds of $3,860,000 from the exercise of warrants prior to their expiration on December 31, 2017."
"We are very pleased with having the resources and capability to harness and propel our performance and efficiency levels, as anticipated demands heighten. We believe that having the funding in place to facilitate expected orders and maximize efficiency is key to being fully prepared for success," stated Colton Melby, CEO of ORHub.
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. On January 11, 2018, the company announced that its subsidiary, SinfoníaRx, has launched its medication therapy management ("MTM") solutions and services for Medicaid beneficiaries in Florida and Virginia under an agreement with a major behavioral health payer. The innovative MTM program includes weekly medication risk assessments, ongoing medication surveillance, and personalized consultation services by highly trained clinical pharmacy teams. The medication assessments and surveillance incorporate proprietary clinical algorithms to identify patients at risk for medication-related problems.
Simulations Plus, Inc. (NASDAQ: SLP) is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. On February 1, 2018, the company announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data. Mark Pflieger, product manager for PKPlus, said: "From our initial release of PKPlus Version 1.0 in August 2016, we have paid careful attention to the feedback given by our customers and prospects. With their guidance and suggestions, and in close collaboration with our colleagues at Cognigen, we now have PKPlus Version 2.0, which contains many new features and improvements."
Fluidigm Corporation (NASDAQ: FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. Recently, the company announced financial results for the fourth quarter and full year ended December 31, 2017. Total revenue for the fourth quarter of 2017 was $27.7 million, an increase of 12% from $24.7 million in the third quarter of 2017 and an increase of 11% from $25.1 million in the fourth quarter of 2016. 2017 operational highlights include: The company signed a multiyear agreement with Ascendas Genomics to support development of molecular diagnostics in China. Ascendas Genomics is developing and commercializing systems and assays using microfluidic technologies included in the Fluidigm Biomark HD and Juno systems.
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. On January 8, 2018, the company announced a definitive agreement to acquire Practice Fusion, for $100 million in cash, subject to adjustment for working capital and net debt. Practice Fusion is a Silicon Valley pioneer in partnering with top-tier life sciences organizations to drive innovation. In combination with Allscripts existing payer and life sciences business, Allscripts expects to expand its big data insights and analytics, data sharing technologies, and clinical trial solutions to enable life sciences organizations to accelerate bringing life-changing therapies to market. Practice Fusion offers an affordable certified cloud-based EHR for traditionally hard-to-reach small, independent physician practices. This strategic acquisition is expected to further advance Allscripts' strategy to offer the most comprehensive, high performing health information technology and solutions.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For ORHUB, Inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by axiom group .Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
For further information: [email protected] +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
Advertisement
There has been positive growth in the medical devices industry over the course of recent years, which is attributed to technological advancements made in development of devices for unmet medical needs. According to Transparency Market Research the global medical device technology market has showcased significant growth over the past few years and is anticipated is projected to grow at a robust CAGR of 4.6% over the forecast period of 2017 to 2025. At this growth rate the market is projected to reach a value of $563,886.5 million by 2025, from $377,562.4 million in 2016. The report points out important market related factors, such as increase in prevalence of cancer and rare diseases, as well as rise in demand for regenerative and cell-based therapies. ORHUB, Inc. (OTC: ORHB), Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC), Simulations Plus, Inc. (NASDAQ: SLP), Fluidigm Corporation (NASDAQ: FLDM), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX)
Advertisement
A pharmaceutical and medical devices industry analyst in Visiongain, Moses Akintomide-Akinwamide, explained: "We expect the increasing move towards personalised therapy to contribute to the expansion of the medical devices market, particularly between 2017 and 2023. Innovations in the field of diagnostics will propel the launch of devices which incorporate biomarkers; leading to swifter patient diagnosis and monitoring… Competition within some of the currently fast growing sectors, such as the cardiology and neurological sectors, will intensify due to the expected launch of innovative products by major companies in mature markets. Moreover, medical device manufacturers will be required to display a high level of cost-effectiveness for their products due to tighter regulatory and reimbursement policies, especially in the emerging economies."
ORHUB, Inc. (OTC: ORHB) on February 6th announced, "that $3.2 million dollars has been successfully raised to further the Company's reach into the marketplace with its revolutionary healthcare IT Vertical Specific Software, which is poised to transform the business of surgery by delivering real-time, casebased surgical data analytics.
This latest funding comes on the heels of the recent warrant program that, at the close of 2017, yielded the Company $3.8 million in working capital. More than $7.0 million raised in past 60 days to drive national sales and scale operations for revolutionary healthcare software.
Offering enhanced capabilities over traditional EHR solutions in the operating room, ORHub's software creates a value-based solution that streamlines surgical care delivery by tracking comprehensive data using proprietary technology. The Company's software has international applications and is particularly ripe for deployment in the United Kingdom, where such solutions are being urgently sought.
ORHub has already secured commitments from three additional major hospitals and has generated interest from countless others. This timely funding will enable the Company's management to meet this demand. ORHub recently announced gross proceeds of $3,860,000 from the exercise of warrants prior to their expiration on December 31, 2017."
"We are very pleased with having the resources and capability to harness and propel our performance and efficiency levels, as anticipated demands heighten. We believe that having the funding in place to facilitate expected orders and maximize efficiency is key to being fully prepared for success," stated Colton Melby, CEO of ORHub.
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. On January 11, 2018, the company announced that its subsidiary, SinfoníaRx, has launched its medication therapy management ("MTM") solutions and services for Medicaid beneficiaries in Florida and Virginia under an agreement with a major behavioral health payer. The innovative MTM program includes weekly medication risk assessments, ongoing medication surveillance, and personalized consultation services by highly trained clinical pharmacy teams. The medication assessments and surveillance incorporate proprietary clinical algorithms to identify patients at risk for medication-related problems.
Simulations Plus, Inc. (NASDAQ: SLP) is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. On February 1, 2018, the company announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data. Mark Pflieger, product manager for PKPlus, said: "From our initial release of PKPlus Version 1.0 in August 2016, we have paid careful attention to the feedback given by our customers and prospects. With their guidance and suggestions, and in close collaboration with our colleagues at Cognigen, we now have PKPlus Version 2.0, which contains many new features and improvements."
Fluidigm Corporation (NASDAQ: FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. Recently, the company announced financial results for the fourth quarter and full year ended December 31, 2017. Total revenue for the fourth quarter of 2017 was $27.7 million, an increase of 12% from $24.7 million in the third quarter of 2017 and an increase of 11% from $25.1 million in the fourth quarter of 2016. 2017 operational highlights include: The company signed a multiyear agreement with Ascendas Genomics to support development of molecular diagnostics in China. Ascendas Genomics is developing and commercializing systems and assays using microfluidic technologies included in the Fluidigm Biomark HD and Juno systems.
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. On January 8, 2018, the company announced a definitive agreement to acquire Practice Fusion, for $100 million in cash, subject to adjustment for working capital and net debt. Practice Fusion is a Silicon Valley pioneer in partnering with top-tier life sciences organizations to drive innovation. In combination with Allscripts existing payer and life sciences business, Allscripts expects to expand its big data insights and analytics, data sharing technologies, and clinical trial solutions to enable life sciences organizations to accelerate bringing life-changing therapies to market. Practice Fusion offers an affordable certified cloud-based EHR for traditionally hard-to-reach small, independent physician practices. This strategic acquisition is expected to further advance Allscripts' strategy to offer the most comprehensive, high performing health information technology and solutions.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For ORHUB, Inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by axiom group .Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
For further information: [email protected] +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
